2 results match your criteria: "Clinic for Otorhinolaryngology - Head and Neck Surgery[Affiliation]"
Heterogeneity of Head and Neck Squamous Cell Carcinoma Stem Cells.
Adv Exp Med Biol
August 2019
Department of Otorhinolaryngology, Head and Neck Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institutes of Health, Berlin, Germany.
Current systemic cancer treatment in head and neck squamous cell carcinoma (HNSCC) is moving toward more personalized approaches such as de-escalation protocols human-papilloma-virus dependent HNSCC or application of checkpoint inhibitors. However, these treatments have been challenged by cancer stem cells (CSC), a small population within the bulk tumor, which are leading to treatment failure, tumor recurrence, or metastases. This review will give an overview of the characteristics of HNSCC-CSC.
View Article and Find Full Text PDFPD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.
Oncotarget
June 2018
University Hospital Schleswig Holstein, Campus Lübeck, Clinic for Otorhinolaryngology - Head and Neck Surgery, Luebeck, Germany.
Article Synopsis
- Cancer immunotherapy has significantly improved with drugs that activate the immune system, particularly through checkpoint inhibitors like PD-1 and PD-L1, leading to notable patient responses.
- However, many patients do not respond to these therapies, creating a need for better predictive indicators of who might benefit.
- This study shows that platelets and immune cells from certain cancer patients and smokers express PD-L1, and treatment with Atezolizumab reduced PD-L1 in platelets, suggesting their potential as biomarkers for therapy success.